세계의 심장 바이오마커 검사 시장 규모는 2023년에 35억 달러, 2030년까지 54억 8,000만 달러에 달하며, 2024-2030년의 예측 기간에 CAGR로 7.77%의 성장이 전망됩니다. 심혈관질환의 유병률 증가, 질환 조기진단 요구의 증가, 노년 인구의 증가, 새로운 임상 관련 심장 바이오마커 식별에서 연구의 진행 등의 요인이 심장 바이오마커 검사 시장의 성장을 적극적으로 자극하고 있습니다.
심장 바이오마커 검사 시장 역학
세계보건기구(WHO)(2023)가 제공한 데이터에 따르면 심혈관질환(CVD)은 전 세계 주요 사망 원인으로 매년 약 1,790만 명의 목숨을 앗아가고 있으며, CVD에는 심근경색, 울혈성 심부전, 급성 관상 동맥 증후군 등이 포함됩니다. 또한 WHO의 같은 자료에 따르면 CVD로 인한 사망자 5명 중 4명 이상이 뇌졸중과 심장마비를 주요 원인으로 꼽고 있으며, 이 중 3분의 1은 70세 미만의 젊은 연령층에서 발생한다고 합니다. 또한 CVD로 인한 사망의 4분의 3 이상이 중저소득 국가에서 발생한다고 밝혔습니다.
유럽심장학회(ESC)(2023)의 데이터에 따르면 매년 유럽에서 심혈관 질환(CVD)은 390만 명의 사망원인이 되고 있으며, 유럽연합(EU)에서는 180만 명 이상이 사망합니다. 유럽에서는 전체 사망자의 약 45%, 유럽연합에서는 37%를 차지합니다.
병력 및 심전도를 기반으로 한 현재의 진단 및 분류 시스템은 심혈관 질환을 적시에 진단하기에 불충분한 것으로 간주됩니다. 그 결과, 일부 환자는 오진으로 인해 부적절한 치료, 관리 및 검사를 받을 수 있습니다. 또한 일부 환자는 진단이 지연되어 조기에 필요한 치료를 늦게 받거나 받지 못하는 경우도 있습니다.
따라서 심혈관계 질환의 조기 진단의 필요성이 심장 바이오마커 검사에 대한 수요를 촉진하고 있습니다. 심장 바이오마커는 심혈관 질환을 적시에 정확하게 진단하고 관리하며 환자의 예후를 개선하는 데 매우 중요합니다. 심근 손상을 조기에 치료하고 회복하기 위해서는 황금기에 진단하는 것이 가장 중요합니다. 심장 바이오마커는 또한 강력한 선별 툴이기도 합니다.
그러나 심근 괴사에 대한 민감도와 특이성이 여전히 부족하여 새로운 특이적 분자를 찾아야 합니다. 바이오마커의 생화학에 대한 이해는 제한적이며, 샘플 수집 및 결과 획득의 어려움은 예측 기간 중 심장 바이오마커 검사 시장의 성장을 저해할 수 있습니다.
심장 바이오마커 검사 시장 부문별 분석
심장 바이오마커 검사 장비 시장의 바이오마커 유형 부문에서는 심장 바이오마커 중 트로포닌 카테고리가 가장 큰 시장 매출 점유율을 차지할 것으로 예측됩니다. 이는 다른 모든 심장 바이오마커 유형 중에서 가장 우수한 심장 바이오마커로 간주되기 때문입니다. 이 단백질은 가장 일반적으로 사용되는 바이오마커로 가장 많이 사용되고 있으며, 가장 민감한 것으로 알려져 있습니다.
트로포닌은 심장마비 후 즉시 혈류로 유입되며, 다른 바이오마커에 비해 장기간 혈류에 머물러 있습니다. 트로포닌은 트로포닌 T와 트로포닌 I의 두 가지 유형로 측정됩니다. 트로포닌 I은 심장 특이성이 높고 크레아티닌 키나아제-MB보다 더 오래 높게 유지되는 것으로 알려져 있습니다. 미국심장협회(AHA)의 최신 가이드라인은 이 바이오마커가 심장마비를 발견하는 데 가장 좋은 바이오마커라고 언급하고 있습니다.
또한 심근경색의 심전도 증거가 불명확한 환자도 있습니다. 이러한 경우, 트로포닌 심근 바이오마커가 널리 사용되고 있습니다.
북미가 전체 심장 바이오마커 검사 시장을 독점할 것으로 예상됩니다.
모든 지역 중 북미가 심장 바이오마커 검사 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 심혈관 질환의 유병률 증가, 우수한 의료 시설, 주요 시장 기업의 존재, 연구개발 활동에 대한 투자 증가 등이 예측 기간 중 전체 심장 바이오마커 검사 시장의 성장을 가속하는 주요 요인이 될 것으로 예상됩니다.
세계의 심장 바이오마커 검사 시장에 대해 조사분석했으며, 시장 규모와 예측, 촉진요인과 과제, 기업과 제품 개요 등을 제공하고 있습니다.
Cardiac Biomarkers Testing Market By Product Type (Instruments and Reagents & Kits), Biomarker Type (Troponin, Creatine Kinase-Mb, B-Type Natriuretic Peptide, Myoglobin, and Others]), Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising geriatric population and increasing need for early disease diagnosis
The global cardiac biomarkers testing market was valued at USD 3.50 billion in 2023, growing at a CAGR of 7.77% during the forecast period from 2024 to 2030 to reach USD 5.48 billion by 2030. Factors such as the increasing prevalence of cardiovascular diseases, the growing need for early disease diagnosis, the rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers are stimulating the growth of the cardiac biomarker testing market positively.
Cardiac Biomarkers Testing Market Dynamics:
As per the data provided by the World Health Organization (2023), cardiovascular diseases (CVDs) are the leading cause of death across the globe, accounting for an estimated 17.9 million lives each year. Some of the CVDs include myocardial infarction, congestive heart failure, acute coronary syndrome, and other conditions. Furthermore, the same data by the WHO presented that over four out of five CVD deaths list strokes and heart attacks as the main cause and one-third of these deaths are said to occur prematurely in people below 70 years of age. The data also states that more than three-quarters of CVD deaths take place in low- and middle-income countries.
According to the data provided by the European Society for Cardiology (ESC) (2023), each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. They represent about 45% of all deaths in Europe and 37% in the European Union.
It has been observed that the current diagnostic and triage systems based on clinical history and electrocardiograms are insufficient for the timely diagnosis of cardiovascular diseases. They may result in some patients being misdiagnosed and being administered inappropriate treatment, care, and investigations. In some patients, the diagnosis is delayed resulting in the late administration (or no administration) of essential early treatment.
Therefore, the need for an early diagnosis of cardiovascular diseases is fuelling the demand for cardiac biomarker testing. Cardiac biomarkers are of great importance in the timely, accurate diagnosis and management of cardiovascular disease as well as in improving the prognosis of the disease for the patient. Diagnosis in the golden period is of utmost importance to institute therapy at the earliest and possibly reverse the myocardial damage. Cardiac biomarkers are also a powerful tool for triaging.
However, the lack of sensitivity and specificity to cardiac muscle necrosis continues to be the need to look for newer specific molecules, limited understanding of the biochemistry of the biomarkers, and challenges in sample collection and obtaining results may restrain the growth of the cardiac biomarker testing market during the forecast period.
Cardiac Biomarker Testing Market Segment Analysis:
Cardiac Biomarker Testing Market by Product Type (Instruments and Reagents & Kits), Biomarker Type (Troponin, Creatine Kinase-MB, Natriuretic Peptide, Myoglobin, and Others]), Application (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the biomarker type segment of the cardiac biomarker testing devices market, the troponin category of cardiac biomarkers is predicted to account for the largest market revenue share. This can be ascribed to the fact that it is considered the best cardiac biomarker among all other cardiac biomarker types. This protein is by far the most commonly used biomarker and has the highest known sensitivity.
Troponin enters the bloodstream soon after a heart attack and remains in the bloodstream for a longer period as compared to other biomarkers. Two forms of troponin may be measured- troponin T and troponin I. Troponin I is considered to be highly specific to the heart and stays higher longer than creatinine kinase-MB. The latest guidelines by the American Heart Association (AHA) mention this biomarker to be the best biomarker for finding a heart attack.
Furthermore, in some patients the electrocardiographic evidence of myocardial infarction remains unclear; in such cases, troponin cardiac biomarkers are extensively used.
North America is expected to dominate the Overall Cardiac Biomarkers Testing Market:
Among all the regions, North America is expected to amass the largest share of the cardiac biomarker testing market. The growing prevalence of cardiovascular diseases, better healthcare facilities coupled with the presence of major market players as well as higher investment in the research and development activities in the region are predicted to be the major influencing factors in driving the overall growth of the cardiac biomarker testing market over the forecast period.
The Centers for Disease Control and Prevention (CDC) 2022, estimated that about 20.1 million adults aged 20 and older had Coronary artery disease (CAD) in the US, in 2020.
Also, the above-mentioned source further stated that in the United States, someone has a heart attack every 40 seconds. Every year, about 805,000 people in the United States have a heart attack. Out of these, 605,000 are a first heart attack, 200,000 happen to people who have already had a heart attack and about 1 in 5 heart attacks are silent-the damage is done, but the person is not aware of it.
As per the information provided by the Centers for Disease Control and Prevention (2023), some of the key risk factors associated with heart diseases are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.
Therefore, the presence of a large patient population suffering from heart disease is one of the major factors contributing to the North American cardiac biomarker testing market growth.
Moreover, the large presence of key market players as well as the launch of new products in the region as a reason for extensive R&D activities also provides favorable conditions for the growth of the North American cardiac biomarker testing market.
Cardiac Biomarkers Testing Devices Market Key Players:
Some of the key market players operating in the cardiac biomarker testing market include Beckman Coulter, Inc., Siemens Healthcare GmbH, Abbott, bioMerieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc., Bio-Rad Laboratories Inc, Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.
Recent Developmental Activities in Cardiac Biomarkers Testing Market:
In April 2021, Roche announced the series of five new intended uses for two key cardiac biomarkers using the Elecsys® technology: high-sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP).
Key Takeaways from the Cardiac Biomarkers Testing Market Report Study
Market size analysis for cardiac biomarker testing market size (2023), and market forecast for 5 years (2024-2030)
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global cardiac biomarker testing market.
Various opportunities available for the other competitor in the cardiac biomarker testing market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current cardiac biomarker testing market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for cardiac biomarker testing market growth in the coming future?
Target Audience who can be benefited from this Cardiac Biomarker Testing Market Report Study
Cardiac biomarkers testing devices products providers
Research organizations and consulting companies
Cardiac biomarkers testing devices -related organization, association, forum, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in cardiac biomarker testing
Various End-Users who want to know more about the cardiac biomarker testing market and the latest technological developments in the cardiac biomarker testing market.
Frequently Asked Questions for Cardiac Biomarker Testing Market:
Cardiac biomarkers are protein molecules that are released into the blood after heart damage or heart stress. These biomarkers act as a potential tool in the detection and diagnosis of various cardiovascular diseases.
The global cardiac biomarkers testing market was valued at USD 3.50 billion in 2023, growing at a CAGR of 7.77% during the forecast period from 2024 to 2030 to reach USD 5.48 billion by 2030.
The major drivers of the global cardiac biomarker testing market growth are the increasing prevalence of cardiovascular diseases, the growing need for early disease diagnosis, the rising aging population, and the advancement in research in identifying novel clinically-relevant cardiac biomarkers.
Some of the key market players operating in the cardiac biomarker testing market include Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, bioMerieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Bio-Rad Laboratories Inc., Eurolyser Diagnostica GmbH, Diagnostic Automation / Cortez Diagnostics, Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, Lepu Medical Technology (Beijing) Co. Ltd., Biosynex and others.
North America is expected to dominate the overall cardiac biomarker testing market during the forecast period, 2024 to 2030. The accumulation of the highest revenue in the market can be ascribed to the rising prevalence of cardiovascular diseases, increasing focus on research and development activities, and the increasing collaborations between key market players in the region.